| Identification | Back Directory | [Name]
TROXACITABINE | [CAS]
145918-75-8 | [Synonyms]
CS-150
L-Oddc
SPD 758
Troxatyl
(-)-Occc
Bch 4556
(-)-Bch 204
TROXACITABINE
α-L-Dioxolane-C
Lamivudine Impurity I
Troxacitabine (SGX-145)
Lamivudine EP Impurity I
Lamivudine Impurity I
(Troxacitabine)
Lamivudine EP Impurity I (Troxacitabine)
4-Amino-1-[(2S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one
4-amino-1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)pyrimidin-2(1H)-one
2(1H)-Pyrimidinone, 4-amino-1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-
2(1H)-Pyrimidinone, 4-amino-1-(-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2S-cis)-
4-amino-1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-1,2-dihydropyrimidin-2-one
TROXACITABINE,2(1H)-PYRIMIDINONE, 4-AMINO-1-(2-(HYDROXYMETHYL)-1,3-DIOXOLAN-4-YL)-, (2S-CIS)- | [EINECS(EC#)]
200-258-5 | [Molecular Formula]
C8H11N3O4 | [MDL Number]
MFCD00871100 | [MOL File]
145918-75-8.mol | [Molecular Weight]
213.19 |
| Chemical Properties | Back Directory | [Melting point ]
176-177° | [alpha ]
D25 -38.33° (c = 0.43 in MeOH). | [Boiling point ]
422.5±55.0 °C(Predicted) | [density ]
1.71±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
14.83±0.10(Predicted) | [color ]
White to Off-White | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
Troxacitabine is a nucleoside analogue with potential anticancer activity. Troxacitabine have been studied in patients with refractory lymphoproliferative diseases. | [Definition]
ChEBI: Troxacitabine is a nucleobase-containing molecular entity and a carbohydrate derivative. | [in vivo]
Troxacitabine is highly active against the Panc-01 model, with TGI levels of 88.5% and 84.3% at the 10 and 25 mg/kg doses, respectively. The mean final tumor weights for animals given troxacitabine are also significantly smaller compared with vehicle controls. Troxacitabine has less activity against the MiaPaCa model[3]. Troxacitabine is very effective in human RCC tumor xenograft models, including CAM-i, A498, RXF-393, and SN12C carcinomas. Very good responses are ob served in animals bearing CAM-i, A498, and RXF-393 RCC tumors given i.p. doses of 10, 25, and 50 mg/kg twice a day for 5 days[2]. |
|
|